Therapieentscheidung bei Patienten mit operablem, nicht metastasiertem Ösophaguskarzinom

Fuchs, Hendrik; Hölscher, Arnulf H.

doi:10.1055/s-0033-1360295

Cited by 6 publications

(2 citation statements)

References 42 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although surgery is a major locoregional treatment52223, the curative potential of CCRT reported in several studies have challenged the role of surgery in esophageal cancer1112. The most appropriate treatment modality for esophageal SCC is still controversial.…”

Section: Discussionmentioning

confidence: 99%

Survival benefit of surgery to patients with esophageal squamous cell carcinoma

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

To assess if surgery provided survival benefit to patients with esophageal squamous cell carcinoma (SCC), we performed a retrospective review of 1230 patients who were newly diagnosed with stage T2-T4 esophageal SCC from 2007 to 2014 in our hospital. There were greater than 70% of patients with age under 65 years, and more than 85% were stage T3-T4 at the time of diagnosis. The median survival time was 1.06 year (95% CI 0.99–1.1 yrs). Survival analyses showed that survival time was significantly associated with age, T stage, clinical lymph node involvement and treatment modality (surgery versus definite chemoradiotherapy). Surgery still possessed a powerful impact on overall survival by multivariable analysis. Death risk of patients treated with curative surgery was significantly lower than those with definite chemoradiotherapy. Furthermore, for patients of stage T3N(+) and T4, surgery combined with (neo-)adjuvant treatment were significantly associated with higher survival rate than surgery alone or definite chemoradiotherapy. In conclusion, the patients who undergo surgery were significantly associated longer survival, therefore, curative resection should be considered for esophageal cancer patients who are medically fit for surgery. Moreover, combined with (neo-)adjuvant treatment is recommended for surgically resectable stage T3-T4 esophageal SCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival benefit of surgery to patients with esophageal squamous cell carcinoma

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Treatment scheme of EAC mainly includes surgery, chemotherapy, and radiotherapy [9]. Surgery is a principal locoregional treatment for patients, and widely performed in locally limited (cT1/T2, N0) and some resectable locally advanced carcinoma (cT3, T4, Nx) [3, 5]. Chemotherapy, as a systemic treatment, is commonly used in locally advanced, metastatic, and recurrent EAC [12–14], but less used in locally early stage [15].…”

Section: Discussionmentioning

confidence: 99%

Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adenocarcinoma

et al. 2016

View full text Add to dashboard Cite

Background & AimsThis study is designed to analyze survival benefit of (neo-) adjuvant radiotherapy to patients with T2-3N0M0 stage esophageal adenocarcinoma (EAC).MethodsT2-3N0M0 stage EAC patients from 2004 to 2012 were searched from the Surveillance Epidemiology and End Results (SEER) data. Clinical factors including age, sex, race were summarized. Univariate, multivariate analysis, and stratified cox analysis based on different T stages were performed to explore the survival effect of (neo-)adjuvant radiotherapy to T2-3N0M0 stage EAC.ResultsT2-3N0M0 stage EAC patients with surgery were more likely to be white race, T3 stage. Univariate analysis showed sex, age, and T stage were the prognostic factors of survival (P<0.05). Multivariate analysis proved (neo-)adjuvant radiotherapy can prolong survival time of T2-3N0M0 stage EAC (P<0.05). Further analysis based on different T stages showed that both neoadjuvant radiotherapy (HR 0.615; 95% CI 0.475-0.797) and adjuvant radiotherapy (HR 0.597; 95% 0.387-0.921) significantly reduced the risk of death of T3N0M0 stage EAC, but neither of which significantly reduced death risk of T2N0M0 stage EAC (P>0.05).Conclusionssex, age are the independent prognostic factors of T2-3N0M0 EAC. Significant survival benefit of (neo-)adjuvant radiotherapy is only observed in patients with T3N0M0 stage EAC, but not in those with T2N0M0 stage.

show abstract

Mortality after esophagectomy is heavily impacted by center volume: retrospective analysis of the Nationwide Inpatient Sample

et al. 2016

View full text Add to dashboard Cite

show abstract

Therapieentscheidung bei Patienten mit operablem, nicht metastasiertem Ösophaguskarzinom

Abstract: Therapeutic decisions in patients with oesophageal cancer should only be made after standardised staging and accurate risk analysis.

Cited by 6 publications

References 42 publications

Survival benefit of surgery to patients with esophageal squamous cell carcinoma

Survival benefit of surgery to patients with esophageal squamous cell carcinoma

Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adenocarcinoma

Mortality after esophagectomy is heavily impacted by center volume: retrospective analysis of the Nationwide Inpatient Sample

Contact Info

Product

Resources

About